Keeping Track Of Withdrawals: Libtayo, Parsaclisib Applications Pulled Due To Postmarketing Issues

 
• By Sue Sutter
  
Ship reversing course
Like a ship at sea, cancer drug sponsors are reversing course on applications under FDA review. • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers